Chargement de votre page…
Clinical parkinsonism & related disorders
Par Liang XN, Wang XY, Zhu JC et 7 autres.
Contenu en anglais
To enhance olfactory screening for Chinese patients with Parkinson's disease (PD) or rapid-eye movement sleep behavior disorder (RBD) by developing and modifying a Chinese Smell Identification Test 12 (CSIT-12).
Ward réunit ces articles dans la même app que vos cartes et vos questions. Un seul compte gratuit pour Ward, Suture, Osler et Prognia.
In a discovery cohort, 69 PD patients and 47 healthy controls (HCs) were tested on 24 distinct odors using the Sniffin' Sticks Screening Test 12 (SSST-12) and CSIT-12. The 12 odors with the highest area under the curve (AUC) were selected to construct the Chinese version of the Sniffin' Sticks Screening Test 12 (C-SSST-12). This newly developed test was then validated in an independent cohort comprising 48 PD patients, 48 RBD patients, and 48 HCs. The reliability and validity of SSST-12, CSIT-12, C-SSST-12, and further abbreviated odor subsets were compared.
Scores on SSST-12, CSIT-12, and C-SSST-12 were significantly lower in both PD and RBD compared to HCs (all P < 0.001). Both the CSIT-12 and SSST-12 demonstrated good discriminative capacity for PD versus HCs (CSIT-12: AUC = 0.832, sensitivity = 77.1%, specificity = 83.3%; SSST-12: AUC = 0.913, sensitivity = 85.4%, specificity = 81.3%) and RBD versus HCs (CSIT-12: AUC = 0.881, sensitivity = 85.4%, specificity = 83.3%; SSST-12: AUC = 0.893, sensitivity = 79.2%, specificity = 81.3%). Notably, the C-SSST-12 achieved the highest discriminative performance for PD versus HCs (AUC = 0.930, sensitivity = 81.3%, specificity = 85.4%) and RBD versus HCs (AUC = 0.949, sensitivity = 89.6%, specificity = 85.4%). A 5-odor CSIT-12 subset and a 3-odor C-SSST-12 subset retained high discriminative validity.
This study highlights the discriminative value of utilizing culturally familiar odors for the screening of PD and RBD in Chinese populations. Furthermore, the abbreviated odor subsets offer highly efficient, rapid screening options suitable for community-based testing and fast-paced clinical environments.
Publié dans Clinical parkinsonism & related disorders. Le résumé est reproduit tel qu’il a été publié et reste l’œuvre de ses auteurs ; lisez l’article complet à la source.
Prognia référence cet article à des fins de documentation et de formation. Il ne constitue pas un avis médical. Lisez toujours l’original et suivez les recommandations en vigueur et les protocoles locaux avant d’agir.
